Held by 2 specialist biotech funds
**OVID Signal Note** Eventide's $7M entry into OVID (4.3M shares, ~2% of float) signals conviction in the company's lead asset OV101 (gaboxadol) for angelman syndrome, a rare developmental disorder with no approved treatments and limited competition. Key catalyst timing: regulatory feedback and potential NDA pathway clarity expected in coming quarters, offering binary but asymmetric risk/reward for a values-focused allocator betting on rare pediatric disease focus.